The LINC Group of Chicago hired a senior executive this monthto head up LINC Scientific Leasing, the company's primary operatingunit. Terrence J. Quinn, former president of Medirec, a short-termhospital equipment lessor, will serve as president and CEO
The LINC Group of Chicago hired a senior executive this monthto head up LINC Scientific Leasing, the company's primary operatingunit. Terrence J. Quinn, former president of Medirec, a short-termhospital equipment lessor, will serve as president and CEO ofLSL, directly under LINC Group president Martin E. Zimmerman.
LINC's medical leasing business has expanded into ancillaryareas, including project finance and venture leasing. Businessunits within the parent company have enlarged concurrently, ashave his responsibilities, Zimmerman said.
"We needed additional management assistance because thebusiness has grown. We have a lot of assets deployed. It requiressomebody full-time, who can manage $800 million worth of assets,"he told SCAN.
Although LINC reduced its size late last year by selling itsmobile imaging services business to Mobile Technology (SCAN 12/12/90),the company has expanded in other areas of medical imaging. LINCacquired two additional companies this month:
The new imaging centers will be combined with existing LINCimaging center management and financing operations, Zimmermansaid.
"We have over 100 MRI installations under lease and havean ownership interest in a number of them. This (the acquisitionof Paul J. Crowe & Associates) is not a major change in direction.All the equipment of Paul Crowe was under LINC leases. It is aconsolidation of what we have," he said.
Management of the combined center operations will be the responsibilityof Kenneth V. Hachikian, a former medical management consultant,who joined LINC last summer.
The MSSI service business has been incorporated into LINC EquipmentServices, an ISO and medical equipment remarketer, Zimmerman said.
LINC acquired an inventory of medical imaging equipment, existingcustomer-service agreements, and 13 engineers with the MSSI acquisition.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.